Improvement of Induction Remission Rate by Modifying the Dose of Idarubicin for Relapsed Childhood Acute Lymphoblastic Leukemia

Relapse is the major cause of treatment failure in acute lymphoblastic leukemia (ALL), yet there is no established treatment for relapsed ALL. To improve the induction remission rate, we modified the dose of idarubicin in the original Children's Cancer Group (CCG)-1884 protocol, and retrospecti...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Yoon, Jong Hyung, Park, Jeong Ah, Kim, Eun Kyung, Kang, Hyoung Jin, Shin, Hee Young, Ahn, Hyo Seop
Materialtyp: Artigo
Språk:Inglês
Publicerad: The Korean Academy of Medical Sciences 2009
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC2672129/
https://ncbi.nlm.nih.gov/pubmed/19399271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3346/jkms.2009.24.2.281
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk